Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Hoffman

Showing results (401-410 of 414) with videos related to

Pageof 42
Sort By:
Biochemistry|August 9, 2017
Sedimentation Velocity Analysis with Fluorescence Detection of Mutant Huntingtin Exon 1 Aggregation in Drosophila melanogaster and Caenorhabditis elegansSurin A Kim, Victoria F D'Acunto, Bashkim Kokona, et al.
The Annals of Thoracic Surgery|July 18, 2024
Consensus Statement: Technical Standards for Thoracoabdominal Normothermic Regional PerfusionJordan R H Hoffman, Matthew G Hartwig, Michael T Cain, et al.
Clinical Genitourinary Cancer|January 1, 2018
Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder CancerLauren C Harshman, Abhishek Tripathi, Matthew Kaag, et al.
Transplantation|July 16, 2024
Consensus Statement: Technical Standards for Thoracoabdominal Normothermic Regional PerfusionJordan R H Hoffman, Matthew G Hartwig, Michael T Cain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Integration of dilated cardiomyopathy genomics with transcriptomics from the human heart implicates regulatory molecular mechanismsConnor S Murray, Chaojie Yang, Suet Nee Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicityElizabeth R Plimack, Jean H Hoffman-Censits, Rosalia Viterbo, et al.
European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.
JCO Precision Oncology|June 12, 2024
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy CandidatesUttam Satyal, Henkel Valentine, David Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2020
Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial CancerJudit Börcsök, Zsofia Sztupinszki, Raie Bekele, et al.
Pageof 42

Showing results (401-410 of 414) with videos related to

Sort By:
Pageof 42
Biochemistry|August 9, 2017
Sedimentation Velocity Analysis with Fluorescence Detection of Mutant Huntingtin Exon 1 Aggregation in Drosophila melanogaster and Caenorhabditis elegansSurin A Kim, Victoria F D'Acunto, Bashkim Kokona, et al.
The Annals of Thoracic Surgery|July 18, 2024
Consensus Statement: Technical Standards for Thoracoabdominal Normothermic Regional PerfusionJordan R H Hoffman, Matthew G Hartwig, Michael T Cain, et al.
Clinical Genitourinary Cancer|January 1, 2018
Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder CancerLauren C Harshman, Abhishek Tripathi, Matthew Kaag, et al.
Transplantation|July 16, 2024
Consensus Statement: Technical Standards for Thoracoabdominal Normothermic Regional PerfusionJordan R H Hoffman, Matthew G Hartwig, Michael T Cain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Integration of dilated cardiomyopathy genomics with transcriptomics from the human heart implicates regulatory molecular mechanismsConnor S Murray, Chaojie Yang, Suet Nee Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicityElizabeth R Plimack, Jean H Hoffman-Censits, Rosalia Viterbo, et al.
European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.
JCO Precision Oncology|June 12, 2024
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy CandidatesUttam Satyal, Henkel Valentine, David Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2020
Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial CancerJudit Börcsök, Zsofia Sztupinszki, Raie Bekele, et al.
Pageof 42